Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind …

KA Papp, RG Langley, M Lebwohl, GG Krueger… - The Lancet, 2008 - thelancet.com
Background Ustekinumab, a human monoclonal antibody against interleukins 12 and 23,
has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of …

Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways

…, AB Begovich, JJ Voorhees, JT Elder, GG Krueger… - Nature …, 2009 - nature.com
Psoriasis is a common immune-mediated disorder that affects the skin, nails and joints. To
identify psoriasis susceptibility loci, we genotyped 438,670 SNPs in 1,409 psoriasis cases …

[PDF][PDF] A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

…, SM Prescott, TJ White, MF Leppert, GG Krueger… - The American Journal of …, 2007 - cell.com
We performed a multitiered, case-control association study of psoriasis in three independent
sample sets of white North American individuals (1,446 cases and 1,432 controls) with …

[HTML][HTML] A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

GG Krueger, RG Langley, C Leonardi… - … England Journal of …, 2007 - Mass Medical Soc
Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the
pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-…

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

…, MJ Cork, X Estivill, AM Bowcock, GG Krueger… - Nature …, 2012 - nature.com
To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis
of 3 genome-wide association studies (GWAS) and 2 independent data sets genotyped …

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

C Antoni, GG Krueger, K de Vlam, C Birbara… - Annals of the …, 2005 - ard.bmj.com
Objectives: To evaluate further in a phase III, double blind trial the efficacy of infliximab in
patients with active psoriatic arthritis (PsA), as observed in the smaller IMPACT trial. Methods: …

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty‐four–week efficacy …

…, I McInnes, P Mease, GG Krueger… - … : Official Journal of …, 2009 - Wiley Online Library
Objective To assess the efficacy and safety of golimumab in patients with active psoriatic
arthritis (PsA). Methods Adult patients with PsA who had at least 3 swollen and 3 tender joints …

[HTML][HTML] Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes

CN Ellis, GG Krueger - New England Journal of Medicine, 2001 - Mass Medical Soc
Background Psoriatic plaques are characterized by infiltration with CD45RO+ memory
effector T lymphocytes. The recombinant protein alefacept binds to CD2 on memory effector T …

Impact of obesity and smoking on psoriasis presentation and management

…, CB Hansen, KP Callis, GG Krueger - Archives of …, 2005 - jamanetwork.com
… Analysis and interpretation of data: Herron, Papenfuss, Callis, and Krueger. Drafting of
the manuscript: Krueger. Critical revision of the manuscript for important intellectual content: …

A randomized trial of etanercept as monotherapy for psoriasis

…, RT Matheson, N Lowe, GG Krueger… - Archives of …, 2003 - jamanetwork.com
… Center, Portland (Dr Matheson); Southern California Dermatology, Santa Monica (Dr Lowe);
Department of Dermatology, University of Utah Medical Center, Salt Lake City (Dr Krueger); …